Parkinsons

Comparison of Parkinson Disease and Huntington Disease

Parkinson Disease:

Primary: The exact cause is unknown, but it is believed to be due to a combination of genetic, lifestyle, and environmental factors such as exposure to toxins.
Secondary: This can result from the prolonged use of certain medications like antipsychotics, head trauma, cerebrovascular issues, or conditions such as brain tumors that impact dopamine-producing neurons.

Huntington Disease:

This is a hereditary disorder caused by a mutation in the HTT gene on chromosome 4, leading to the progressive degeneration of nerve cells in the brain. It follows an autosomal-dominant inheritance pattern, meaning only one parent needs to carry the defective gene for the child to inherit the disease.

Parkinson Disease:

It is a chronic and progressive neurological condition characterized by the death of dopaminergic neurons in the substantia nigra. This results in a decrease in dopamine levels, leading to an imbalance in neurotransmitters such as GABA and glutamate. This biochemical imbalance contributes to the hallmark symptoms of the disease, including tremors, rigidity, and bradykinesia.

Huntington Disease:

Inversely, Huntington's disease affects the basal ganglia and cortex, primarily altering the levels of dopamine, which significantly impacts motor control and voluntary movements. As the disease progresses, it causes atrophy of the brain structures and leads to a myriad of psychological symptoms due to its effect on the frontal lobes.

Parkinson Disease:

The course typically spans over 10-20 years, where patients experience a gradual decline in cognitive function, mobility, and abilities related to activities of daily living (ADLs). Patients often succumb to complications associated with immobility, such as pneumonia or cardiovascular issues.

Huntington Disease:

The disease generally has a duration of about 15-20 years from the onset of symptoms. Patients experience a progressive decline with the emergence of chorea—a series of rapid, uncontrolled movements—as well as cognitive decline and emotional disturbances, with complications related to mobility leading to eventual death.

Parkinson Disease:

Primary: Genetic factors play a role, predominantly affecting males aged 30-50 years, with a noted family history potentially increasing risk.
Secondary: Previous traumatic brain injury, especially in susceptible individuals, can increase the likelihood of developing the disease later in life.

Huntington Disease:

A significant risk factor is advancing age, particularly those over 40 years, as the disease symptoms usually manifest in mid-adulthood.

For both conditions, implementing safety measures is critical to prevent falls and injuries. Providing assistance with ADLs and mobility tailored to the disease stage is essential for maintaining quality of life.

Stage 1: Initial Stage
- Symptoms usually present unilaterally, with minimal weakness, hand tremors, and slight difficulty in movements.
Stage 2: Mild Stage
- Symptoms become bilateral, with an emerging masklike facial expression and noticeable slow and shuffling gait.
Stage 3: Moderate Disease
- Increased postural instability arises, along with significant gait disturbances, leading to an increased risk of falls.
Stage 4: Severe Disability
- Patients experience akinesia (loss of voluntary movement) and extreme rigidity, which severely compromises mobility.
Stage 5: Complete ADL Dependence
- In this final stage, patients are totally dependent on caregivers for all activities of daily living, showcasing profound motor and cognitive impairment.

Allowing extra time for patient responses is crucial to accommodate their motor changes.
Medications should be administered on a strict schedule to ensure therapeutic effectiveness and minimize symptoms.
Pain management and addressing any tingling sensations in limbs through pharmacological interventions are vital components of care.
Monitoring for side effects from medications, such as orthostatic hypotension (a drop in blood pressure upon standing) and hallucinations, is essential for patient safety.
Implementing fall precautions according to established protocols is important to reduce the risk of injuries.
Collaborating with physical and occupational therapists enables the development of personalized therapy programs to enhance mobility.
Scheduling activities around the patient's peak functioning times can help optimize their participation in daily activities.
Teaching patients effective communication strategies can mitigate frustration and improve interactions; referrals to speech-language pathologists may be warranted.
It’s important to provide dietary consultations for high-protein, high-calorie meals to counteract weight loss due to the disease.
Ongoing assessments for emotional and mental health issues are crucial, focusing on identifying strengths and addressing conditions like depression or anxiety as they arise.

Dopamine Agonists:
- These drugs can lead to orthostatic hypotension and hallucinations; patients should be cautioned against using heavy machinery while symptomatic. Older adults should be particularly monitored due to a higher risk of severe side effects.
MAOI-B Drugs:
- These medications work by slowing the activity of the enzyme MAO-B, which breaks down dopamine, potentially offering neuroprotective effects. Patients must be advised to avoid tyramine-rich foods (e.g., aged cheese, cured meats, red wine) for at least 14 days after discontinuation to prevent hypertensive crises.
Pimavanserin:
- This medication is contraindicated for patients with cardiac dysrhythmias due to the risk of QT prolongation. Patients should report any irregular heart rhythms promptly, and caution should be exercised when used alongside CYP3A4 inhibitors, necessitating careful dosage adjustments.